| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-06-20 | Ultragenyx Pharmaceutical (USA - CA) | nomination |
Rare diseases | Nomination | ||
| 2016-06-20 | Ultragenyx Pharmaceutical (USA - CA) Takeda Pharmaceutical (Japan) | novel products for rare and ultra-rare genetic diseases | development commercialisation |
Rare diseases - Genetic diseases | Development agreement | |
| 2016-06-19 | Txcell (France) Lentigen Technology , a wholly-owned subsidiary of Miltenyi Biotec (Germany) | HLA-A2 CAR lentiviral vector | prevention of chronic rejection after organ transplantation. |
|
Transplantation | Services contract |
| 2016-06-17 | Cell Medica (UK) Baylor College of Medicine (USA - TX) | cellular immunotherapy products | development licensing |
Cancer - Oncology | Development agreement | |
| 2016-06-17 | Takeda Pharmaceutical (Japan) Tri-Institutional Therapeutics Discovery Institute (USA - NY) | antibody drug discovery program | collaboration |
Collaboration agreement | ||
| 2016-06-17 | Amgen (USA - CA) | nomination |
Nomination | |||
| 2016-06-17 | Valeant Pharmaceuticals (Canada) | construction of new premises |
Construction of new premises | |||
| 2016-06-17 | Ariad Pharmaceuticals (USA - MA) | restructuring |
Cancer - Oncology - Rare diseases | Restructuring | ||
| 2016-06-17 | Ariad Pharmaceuticals (USA - MA) | restructuring |
Cancer - Oncology - Rare diseases | Restructuring | ||
| 2016-06-16 | Hoopika Biotech (Austria) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2016-06-16 | Takeda Pharmaceutical (Japan) M2Gen (USA - FL) | Oncology Research Information Exchange Network (ORIEN) Avatar™ Research Program | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2016-06-16 | Pfizer (USA - NY) | construction of a production plant construction of new premises
|
Technology - Services | Construction of a production plant | ||
| 2016-06-16 | Takeda Pharmaceutical (Japan) Roivant Sciences (Switzerland) Myovant Sciences (USA - CA) | relugolix (TAK-385), RVT-602 (TAK-448) | uterine fibroids, endometriosis, prostate cancer | establishment of a new company licensing |
Cancer - Oncology - Women health | Licensing agreement |
| 2016-06-15 | Medivir (Sweden) | restructuring |
Infectious diseases | Restructuring | ||
| 2016-06-15 | ProBioGen (Germany) Thermo Fisher Scientific (USA - MA) | GlymaxX® Antibody Glyco-Engineering technology | licensing |
Technology - Services - Allergic diseases | Licensing agreement | |
| 2016-06-15 | MDxHealth (Belgium) Qiagen (The Netherlands) | methylation-specific PCR (MSP) technology | cervical cancer | licensing |
Cancer - Oncology - Diagnostic | Licensing agreement |
| 2016-06-15 | Argos Therapeutics (USA - NC) Adaptive Biotechnologies (USA - WA) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2016-06-14 | Shire (UK - USA) Pfizer (USA - NY) | PF-00547659 | moderate-to-severe inflammatory bowel disease (IBD) including ulcerative colitis and Crohn’s disease | licensing | Inflammatory diseases - Gastrointestinal diseases | Licensing agreement |
| 2016-06-14 | Minoryx Therapeutics (Spain) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-06-13 | Bionor Pharma (Norway) | update |
Infectious diseases | Establishment of a new subsidiary in the EU |
